TNFSF10 and neoplasm: While TRAIL can be a very potent tumoricidal agent due to its ability to target both the tumor cells and the tumor vasculature [3], administration of TRAIL to resistant tumors may trigger invasiveness and promote metastasis [4–6] further highlighting the need for robust biomarkers predicting TRAIL-responsiveness.